A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database

BJU International

Volumn 107, Issue 6, 2011, Pages 924-928

  Kim, Howard S ^a,b   Moreira, Daniel M ^a,b   Smith, Matthew R ^c   Presti Jr , Joseph C ^d,e   Aronson, William J ^f   Terris, Martha K ^f,g   Kane, Christopher J ^h   Amling, Christopher L ⁱ   Freedland, Stephen J ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g MEDICAL COLLEGE OF GEORGIA   (United States)

^h UCSD MEDICAL CENTER   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Androgen deprivation; Prostate cancer; Side effects; Weight

Indexed keywords

GONADORELIN AGONIST;

AGED; ARTICLE; CONTROLLED STUDY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

AGED; ANDROGEN ANTAGONISTS; ANDROGENS; BODY WEIGHT; DATABASES, FACTUAL; EPIDEMIOLOGIC METHODS; HUMANS; MALE; PROSTATIC NEOPLASMS; WEIGHT GAIN;

EID: 79952607568     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09679.x     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49
2. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with nodepositive prostate cancer. N Engl J Med 1999; 341: 1781-8
3. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 2006; 106: 581-8 (Pubitemid 43157621)
4. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91: 1305-8
5. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010; 102: 39-46
6. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-56 (Pubitemid 46630983)
7. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007; 99: 1516-24 (Pubitemid 351767235)
8. Basaria S, Lieb J 2nd, Tang AM et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002; 56: 779-86 (Pubitemid 34785910)
9. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004; 63: 742-5 (Pubitemid 38479421)
10. Smith MR, Finkelstein JS, McGovern FJ et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599-603 (Pubitemid 34158224)
11. Galvao DA, Spry NA, Taaffe DR et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 2008; 102: 44-7 (Pubitemid 351799442)
12. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000; 163: 1632-42 (Pubitemid 30366704)
13. Smith MR, Lee H, McGovern F et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008; 112: 2188-94 (Pubitemid 351628628)
14. D'Amico AV, Denham JW, Crook J et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007; 25: 2420-5 (Pubitemid 46999213)
15. Braga-Basaria M, Dobs AS, Muller DC et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24: 3979-83 (Pubitemid 46630747)
16. Lee H, McGovern K, Finkelstein JS, Smith MR. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 2005; 104: 1633-7 (Pubitemid 41437426)
17. Smith MR. Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer. Cancer Metastasis Rev 2002; 21: 159-66 (Pubitemid 35351836)
18. Alibhai SM, Duong-Hua M, Sutradhar R et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009; 27: 3452-8
19. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007; 110: 1493-500 (Pubitemid 47463063)
20. Efstathiou JA, Bae K, Shipley WU et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 2009; 27: 92-9
21. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005; 103: 1615-24 (Pubitemid 40490022)